Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?

Saved in:

Bibliographic Details
Main Authors:	Hikmet COBAN, Mustafa COLAK, Merve YUMRUKUZ ŞENEL, Muzaffer GUNES, Nurhan SARIOGLU, FUAT EREL
Format:	Article
Language:	English
Published:	Galenos Publishing House 2025-06-01
Series:	Medeniyet Medical Journal
Subjects:	pirfenidone nintedanib radiation pneumonitis antifibrotic treatment
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=medeniyet&un=MEDJ-87393
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
by: Nesrin Ocal, et al.

Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis
by: Yiting Qiu, et al.
Published: (2025-07-01)

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
by: Sebastian Majewski, et al.
Published: (2025-06-01)

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases
by: Tao Wang, et al.
Published: (2025-04-01)

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
by: Stefano Kette, et al.
Published: (2025-03-01)

Impact of Pirfenidone on Patient-Reported Outcomes in Patients With Idiopathic Pulmonary Fibrosis From the Pulmonary Fibrosis Foundation Patient RegistryTake-home Points
by: Mohleen Kang, MD, MS, et al.
Published: (2024-12-01)

Acute thrombocytopenia and fibrinogen reduction occurring after nintedanib treatment for immune checkpoint inhibitor-related pneumonia: a case report
by: Jian Zheng, et al.
Published: (2025-08-01)

Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database
by: Yasuhiro Kondoh, et al.
Published: (2025-05-01)

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France
by: Emilie Clay, et al.
Published: (2019-01-01)

Pulmonary fibrosis complicated by lung cancer: bibliometric analysis from 2004 to 2024 - research status, trends and future directions
by: Boyang Li, et al.
Published: (2025-04-01)

Fibrotic Hypersensitivity Pneumonitis: A Diagnostic Challenge Leading to Lung Transplantation
by: Maria-Daniela Mot, et al.
Published: (2025-05-01)

Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis
by: Chiao-Yin Sun, et al.
Published: (2025-01-01)

Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery
by: Stefano Bongiolatti, et al.
Published: (2024-11-01)

Comparative efficacy of Pirfenidone and Meloxicam on early radiotherapy-induced anal sphincter dysfunction in rats
by: Dragoș Viorel Scripcariu, et al.
Published: (2025-03-01)

Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype
by: L. P. Ananieva, et al.
Published: (2021-01-01)

A clinical case of idiopathic pulmonary fibrosis against the background of comorbid pathology
by: A. V. Teteneva, et al.
Published: (2021-10-01)

Treatable traits in idiopathic pulmonary fibrosis: focus on respiratory tract infections—a systematic review and a meta-analysisResearch in context
by: Zsombor Matics, et al.
Published: (2025-01-01)

The pulmoprotective effects of pirfenidone against paraquat-induced pulmonary toxicity: a systematic review
by: Sajjad Sadeghi, et al.
Published: (2025-06-01)

Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis
by: Jingran Xu, et al.
Published: (2025-08-01)

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
by: E. L. Nasonov, et al.
Published: (2022-12-01)

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
by: E. L. Nasonov, et al.
Published: (2018-06-01)

Acneiform drug eruption from pirfenidone
by: Jordyn Puccio, BS, et al.
Published: (2025-07-01)

ADDING NINTEDANIB TO IMMUNOSUPPRESSIVE THERAPY IN CONNECTIVE TISSUE RELATED INTERSTITIAL LUNG DISEASES; CASE SERIES BASED ON REAL-LIFE DATA FROM A SINGLE CENTRE
by: Burak Okyar, et al.
Published: (2025-03-01)

The updated evidence of pirfenidone treated silicosis based on network pharmacology, molecular docking and experimental validation
by: Sirong Chang, et al.
Published: (2025-05-01)

Predictive value of machine learning for radiation pneumonitis and checkpoint inhibitor pneumonitis in lung cancer patients: a systematic review and meta-analysis
by: Shenghan Wang, et al.
Published: (2025-07-01)

The unexplored mechanism of antitumoral effect of pirfenidone in melanoma cells
by: Melissa Marchese, et al.
Published: (2025-08-01)

Pneumonitis secondary to intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy
by: Komeil Alattar, MBBS, PGCert, et al.
Published: (2025-09-01)

Estimated prevalence and incidence of hypersensitivity pneumonitis in Japan
by: Tsukasa Okamoto, et al.
Published: (2025-01-01)

Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone
by: Tomohiko Yagi, et al.
Published: (2025-02-01)

Affinity of Nintedanib Towards New Candidate Target for Idiopathic Pulmonary Fibrosis
by: Hari Baskar Balasubramanian, et al.
Published: (2024-08-01)

Recrudescence of Natalizumab‐Induced Pneumonitis and Peripheral Hypereosinophilia: Case Report and Literature Review
by: Gerardo Arwi, et al.
Published: (2025-04-01)

Pirfenidone reduces ovarian fibrosis and improves PCOS in letrozole-induced rat model
by: Ayşe Çakır Gündoğdu, et al.
Published: (2025-06-01)

Trajectory of bodyweight and skeletal muscle mass in patients treated with nintedanib for idiopathic pulmonary fibrosis
by: Hiromi Tomioka, et al.
Published: (2024-12-01)

Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients
by: Simón A. Ojeda-Duran, et al.
Published: (2020-05-01)

Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study
by: Natalia Fernández Núñez, et al.
Published: (2025-01-01)

Nintedanib alleviates hyperoxia-induced lung injury via targeting NF-κB signalling pathway in rat model of bronchopulmonary dysplasia
by: Rui Hao, et al.
Published: (2025-06-01)

Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report
by: María Espinosa Bosch, et al.
Published: (2016-07-01)

Successful Tepotinib Treatment in MET Exon 14 Skipping Mutation‐Positive Lung Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through Nintedanib Combination
by: Yoshiki Kato, et al.
Published: (2025-06-01)

Korean Guidelines for the Diagnosis and Management of Interstitial Lung Diseases: Hypersensitivity Pneumonitis
by: Byoung Soo Kwon, et al.
Published: (2025-07-01)